Evidence map›Paper›PMID 35585909›Full record

ReviewDementia and neurocognitive disorders2022

Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association.

Kee Hyung Park, Jae-Won Jang, Jeewon Suh, SangHak Yi, Jae-Sung Bae, Jae-Sung Lim, Hyon Lee, Juhee Chin, Young Ho Park, Yun Jeong Hong and 2 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dementia and neurocognitive disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Kee Hyung ParkDepartment of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.ORCID https://orcid.org/0000-0001-6847-6679
Jae-Won JangDepartment of Neurology, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea.ORCID https://orcid.org/0000-0003-3540-530X
Jeewon SuhDepartment of Neurology, National Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0003-3509-6447
SangHak YiDepartment of Neurology, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea.ORCID https://orcid.org/0000-0002-2701-9807
Jae-Sung BaeDepartment of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID https://orcid.org/0000-0002-8270-0072
Jae-Sung LimDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-6157-2908
Hyon LeeDepartment of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.ORCID https://orcid.org/0000-0002-0273-8960
Juhee ChinDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-3784-9716
Young Ho ParkDepartment of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.ORCID https://orcid.org/0000-0002-2756-1786
Yun Jeong HongDepartment of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.ORCID https://orcid.org/0000-0002-4996-4981
Geon Ha KimDepartment of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-5395-1924
Academic Committee of the Korean Dementia Association
Gachon University Gil Medical Center · KREwha Womans University · KRKangwon National University Hospital · KRKyungpook National University · KRNational Medical Center · KRSamsung Medical Center · KRSeoul National University Bundang Hospital · KRThe Catholic University of Korea Uijeongbu St. Mary's Hospital · KRUlsan College · KRWonkwang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer's dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD's diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.

Indexed as

Alzheimer DiseaseCardiometabolic Risk FactorsGenetic ResearchNeuroimagingNeuroinflammationPrevention

Identifiers

PMID35585909
PMCPMC9085535
OpenAlexW4280621351

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.